Expression of costimulatory molecules B7‐1 (CD80) and B7‐2 (CD86) on human hepatocellular carcinoma

Costimulation mediated by costimulatory molecules, such as B7‐1 and B7‐2, which are ligands for the CD28/cytolytic T lymphocyte associated antigen (CTLA)‐4 counter‐receptor, plays an important role in the induction of T cell‐mediated antitumor immunity. We investigated the expressions of B7‐1, B7‐2, and human leukocyte antigen (HLA) class I in seven human hepatocellular carcinoma (HCC) cell lines by reverse transcription‐polymerase chain reaction (RT‐PCR) and flow cytometric analysis. RT‐PCR showed that all these human HCC cell lines were positive for B7‐1 and B7‐2 at the messenger RNA (mRNA) level. Flow cytometric analysis revealed that they all expressed B7‐1, B7‐2, and HLA class I on the cell surface. However, the expression levels of B7‐1 and B7‐2 were very low whereas those of HLA class I were high. B7‐1 and B7‐2 expression could be increased by treatment with interferon α and interferon γ in a dose‐dependent manner, although the expression levels of B7‐1 and B7‐2 after interferon treatment remained low. By transfecting Hep3B cells with a plasmid containing human B7‐1 complementary cDNA (cDNA), we were able to establish Hep3B cell lines strongly expressing B7‐1. From mixed lymphocytes and tumor cultures analysis, the primary cytolytic activity against parental Hep3B cells could be induced effectively by B71‐transfected Hep3B cells. These findings suggested that B7‐1 gene transfer is the best way to induce strong expression of this molecule and this might be useful for immuno‐gene therapy against human HCC.

[1]  P. Hersey,et al.  Expression of the co‐stimulatory molecule CD40 on melanoma cells , 1996 .

[2]  M. Kojiro,et al.  Expression of intercellular adhesion molecule 1 in human hepatocellular carcinoma , 1995, Hepatology.

[3]  G. Trinchieri,et al.  B7-1 and interleukin 12 synergistically induce effective antitumor immunity. , 1995, Cancer research.

[4]  L. Chen,et al.  Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. , 1995, Journal of immunology.

[5]  P. Stastny,et al.  Population diversity of B-locus alleles observed by high-resolution DNA typing. , 1995, Tissue antigens.

[6]  P. Linsley,et al.  Studies on the interdependence of gp39 and B7 expression and function during antigen‐specific immune responses , 1995, European journal of immunology.

[7]  S. Y. Yang,et al.  SSOP typing of the Tenth International Histocompatibility Workshop reference cell lines for HLA-C alleles. , 1994, Tissue antigens.

[8]  J. Bluestone,et al.  The B7 and CD28 receptor families. , 1994, Immunology today.

[9]  Lieping Chen,et al.  Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. , 1994, Journal of immunology.

[10]  P. Linsley,et al.  Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. , 1994, Journal of immunology.

[11]  V. Barnaba,et al.  Human hepatoma cells expressing MHC antigens display accessory cell function: dependence on LFA-1/ICAM-1 interaction. , 1994, Immunology.

[12]  J. Allison,et al.  CD28-B7 interactions in T-cell activation. , 1994, Current opinion in immunology.

[13]  L. Shen,et al.  Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. , 1994, Journal of immunology.

[14]  Y. Wu,et al.  T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells , 1994, The Journal of experimental medicine.

[15]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[17]  J. Johnston,et al.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.

[18]  J. Bluestone,et al.  Expression and functional significance of an additional ligand for CTLA-4. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Gribben,et al.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production , 1993, The Journal of experimental medicine.

[20]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[21]  L. Lanier,et al.  B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.

[22]  P. Linsley,et al.  Costimulation of T cells for tumor immunity. , 1993, Immunology today.

[23]  G. Starling,et al.  B7/BB-1 is a leucocyte differentiation antigen on human dendritic cells induced by activation. , 1993, Immunology.

[24]  J. Gribben,et al.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Freeman,et al.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Chow,et al.  Recombinant interferon‐α in inoperable hepatocellular carcinoma: A randomized controlled trial , 1993 .

[27]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[28]  P. Linsley,et al.  The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.

[29]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[30]  P. Linsley,et al.  Costimulation of T-cell growth. , 1992, Current opinion in immunology.

[31]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[32]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[33]  J. Banchereau,et al.  IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. , 1991, International immunology.

[34]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[35]  G. Freeman,et al.  B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. , 1989, Journal of immunology.

[36]  K. Arai,et al.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat , 1988, Molecular and cellular biology.

[37]  T. Yokochi,et al.  B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. , 1982, Journal of immunology.